Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (
NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinical data for rezafungin in six poster presentations at IDWeek taking place in-person in Washington, D.C. from October 19-23, 2022. The company will also participate in a pipeline symposium focused on new antimicrobials and ID diagnostics.
Cidara Therapeutics Receives $11.1 Million Milestone Payment from MundipharmaMilestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rezafungin for the treatment of candidemia and invasive candidiasis. The company also announced that it has entered into a license agreement with Melinta Therapeutics under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the U.S. Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the treatment of candidemia and invasive candidiasis, as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation.
